A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight
NCT07605052 · Completed
Last updated 2026-09-22This study compares how two different versions of the drug cagrilintide are absorbed into the bloodstream in adults who are overweight or have obesity.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 50 people
Who can join Ages 18–64 · all sexes
Timeline Started 2026-05 · est. completion 2026-08
Where 1 site · United States
What this study is testing ClinicalTrials.gov NCT07605052 ↗
Description as written by the study sponsor.
The purpose of this clinical study is to compare 2 different versions cagrilintide and see how these work in people living with excess body weight. Participant will get either cagrilintide B or cagrilintide D injections. Which treatment participant will get is decided by chance. Participant will be in this clinical study for about 14 weeks.
Treatments tested
- Cagrilintide B Drug
Cagrilintide B will be administered subcutaneously.
- Cagrilintide D Drug
Cagrilintide D will be administered subcutaneously.
| Main thing measured | AUCss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Conditions studied | Overweight, Obesity |
| GLP-1 drugs | cagrilintide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07605052 ↗